Drugs / [68Ga]Ga-P15-041
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06455722 | Jan → Dec 2024 | bone neoplasm | First Affiliated Hospital of Fujian Medical University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga]Ga-P15-041 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06455722 ↗ |
| Known as | P15-041 | “The laboratory of Hank F. Kung at the University of Pennsylvania had developed a new generation of Gallium-68 labeled radiopharmaceutical P15-041 (\[68Ga\]Ga-P15-041) based on...” NCT06455722 ↗ |
| Modality | Diagnostic / imaging agent | “Tracer doses of \[68Ga\]Ga-P15-041 will be used to image lesions by PET/CT.” NCT06455722 ↗ |
| Route | Intravenous | “Intravenous injection” NCT06455722 ↗ |